Phase II study of weekly paclitaxel (PAC) and bryostatin-1 (BRYO) in hormone refractory prostate cancer (HRPC)

G. R. Hudes,P. Celano,F. Torti,A Tabatabai,A. Murgo,A. Hussain

Phase II study of weekly paclitaxel (PAC) and bryostatin-1 (BRYO) in hormone refractory prostate cancer (HRPC)

2005

G. R. Hudes
P. Celano
F. Torti
A Tabatabai
A. Murgo
A. Hussain

4714 Background: Augmenting the antitumor activity of taxanes is a logical approach to improve treatment for patients with HRPC. BRYO, an inhibitor of protein kinase C and CDK2 activity, enhances t...

Keywords:

Phases of clinical research
Paclitaxel
Bryostatin 1
Hormone refractory prostate cancer
Oncology
Internal medicine
Medicine
Cyclin-dependent kinase 2
weekly paclitaxel
Protein kinase C
antitumor activity
logical approach

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations